Abstract 60P
Background
A group of spindle cell tumors with characteristic morphologic features and recurrent gene rearrangements has recently been described. Genome-wide DNA methylation profiling has emerged as a powerful tool for both robust classification of known sarcoma entities and identification of novel and clinically relevant subclasses of soft tissue tumors with characteristic alterations.
Methods
Anchored Multiplex polymerase chain reaction amplicons were sequenced on Illumina MiSeq and the data were analyzed using the Archer and Arriba software. Genome-wide DNA methylation profiling was performed using Infinium Methylation EPIC (EPIC) BeadChip (Illumina).
Results
We identified 6 spindle cell sarcoma cases with rearrangement/SNV in BRAF gene, 3 pediatric spindle cell sarcomas with NTRK1 fusion, 1 high-grade sarcoma with ALK fusion and 1 pediatric sarcoma with tyrosine-kinase duplication of EGFR gene. We show that CDKN2A deletion was the most prevalent DNA copy number aberration in spindle cell sarcomas for which this deletion is a typical change and connecting element across different subgroups of spindle cell sarcomas and this change was associated with poor clinical outcome. DNA methylation profiling demonstrated that 5 of our BRAF altered spindle cell sarcomas clustered within MPNST-like methylation class, but methylation analysis classified the next BRAF rearranged case (with CUX1::BRAF fusion) near to angiomatoid fibrous histiocytomas or inflammatory myofibroblastic tumors. Our patients with LMNA::NTRK1 fusion gene clustered within dermatofibrosarcoma protuberans methylation class. Methylation analysis of the sample with ALK fusion did not classify the sample in any of the defined class of methylation classifier.
Conclusions
The current study demonstrates, that all detected rearrangements in our spindle cell cohort are potentially therapeutically targetable. We provide evidence for the pathobiological and epigenetical heterogeneity of spindle cell sarcomas generally, and also of spindle cell sarcomas that shows alteration of the tyrosin-kinase genes.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Ministry of Health, Czech Republic - Conceptual Development of Research Organization, Motol University Hospital, Prague, Czech Republic 00064203.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
94P - Harnessing circulating tumor DNA in bronchoalveolar lavage fluid for precise molecular diagnosis of NSCLC
Presenter: Frank Borm
Session: Cocktail & Poster Display session
Resources:
Abstract
95P - Automatic data processing to identify EGFR mutations in pathology reports of patients with non-small cell lung cancer (NSCLC)
Presenter: Betzabel Cajiao Garcia
Session: Cocktail & Poster Display session
Resources:
Abstract
96P - Analysis of concordance between microsatellite instability by next generation sequencing (NGS-MSI) and mismatch repair deficiency by immunohistochemistry (IHC-MMR) in endometrial cancer (EC) patients
Presenter: Simona Duranti
Session: Cocktail & Poster Display session
Resources:
Abstract
97P - Prospects of liquid biopsy in determining prognosis in children with HGG and DIPG
Presenter: Olga Regentova
Session: Cocktail & Poster Display session
Resources:
Abstract
98P - Liquid biopsy in NSCLC: A promising tool to predict immunotherapy response
Presenter: Ana Fernández
Session: Cocktail & Poster Display session
Resources:
Abstract
99P - Comprehensive genomic sequencing as an ancillary diagnostic tool for pathologists
Presenter: Dan Miller
Session: Cocktail & Poster Display session
Resources:
Abstract
100P - Standard serum biomarkers to help predict a cancer diagnosis in patients with non-specific symptoms: Data from Guy´s rapid diagnostic clinic
Presenter: Maria Monroy Iglesias
Session: Cocktail & Poster Display session
Resources:
Abstract
101P - Patient-derived organoids to optimize CDK4/6 inhibitor-based treatment selection in early breast cancer
Presenter: Carla Alves
Session: Cocktail & Poster Display session
Resources:
Abstract
102P - MicroRNAs in urine and saliva as non-invasive biomarkers of minimal residual disease in pediatric acute lymphoblastic leukemia
Presenter: Alejandra Pando-Caciano
Session: Cocktail & Poster Display session
Resources:
Abstract
103P - MSI detection by NGS using tumor samples and liquid biopsy for patients with solid tumors: A single institution experience
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract